DDInter1595 DDInter1376
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Rilpivirine {u} (Compound) resembles {v} (Compound) Etravirine
Rilpivirine {u} (Compound) binds {v} (Gene) CYP3A4
Rilpivirine {u} (Compound) is included by {v} (Pharmacologic Class) Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Rilpivirine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Rilpivirine {u} may lead to a major life threatening interaction when taken with {v} Ranitidine
Rilpivirine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Rilpivirine (Compound) resembles Etravirine (Compound)
Rilpivirine (Compound) binds CYP3A4 (Gene)
Rilpivirine (Compound) is included by Non-Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Rilpivirine (Compound) causes Blood creatinine increased (Side Effect)
Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Rilpivirine may lead to a major life threatening interaction when taken with Lumacaftor
Rilpivirine may lead to a major life threatening interaction when taken with Ranitidine
Rilpivirine (Compound) resembles Pazopanib (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib